# Preclinical Imagining Labs

> **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $38,853

## Abstract

PROJECT SUMMARY/ABSTRACT
The Preclinical Imaging Laboratory Shared Resource (PCI) mission is to foster cutting-edge research by
providing highly specialized expertise and service in noninvasive rodent imaging to Perlmutter Cancer Center
(PCC) members in a collaborative environment. Under the expert direction of Youssef Wadghiri, PhD, PCI
provides rodent imaging modalities equivalent to those available in clinical settings. Wadghiri has 32 years of
experience in imaging, 11 years as shared resource director, and an international reputation in developing
molecular imaging strategies, image-guided interventions, instruments, and molecular probes. PCI is further
staffed by an Assistant Director and 3 highly trained scientists. PCI has continued to update its instrument fleet
with 6 new scanners, resulting in a total of 18 instruments across 4 buildings throughout the NYU Grossman
School of Medicine campus, while expanding its imaging capabilities from 5 to 7 modalities. The wide variety of
available imaging modalities (MRI, PET, SPECT, CT, Bioluminescence/Fluorescence imaging, high frequency
ultrasound, and dual energy X-ray absorptiometry) facilitate cost-effective, noninvasive screening and
longitudinal examination of all rodent organs in cancer models at the anatomical, metabolic, and molecular levels.
PCI is critical to the research of three PCC Research Programs, CGD, CCB, and TIM; during the 2018-2022
funding cycle, 45 peer-reviewed funded grants and 76 publications used PCI resources and expertise. We
regularly assess PCC member needs and satisfaction via surveys and an internal advisory board, and ensure
best practices, quality control, instrument maintenance, and data provenance for scientific rigor and
transparency. The Specific Aims of PCI are: 1) to provide multiple small animal imaging instruments and
technologies to PCC members, including MRI, PET, SPECT, CT, high frequency ultrasound, DEXA, and
bioluminescence and fluorescence imaging, 2) to provide PCC researchers with specific expertise, i.e., assist
with experimental design, direct instrumentation technical support, and expert data analysis and interpretation,
and to facilitate data sharing and management through state-of-the-art software and high-performance, secure
servers, 3) to implement novel technologies and methodologies for cutting-edge imaging support including
interventional imaging approaches, and 4) to foster an educational and training environment to the PCC research
community on learning how imaging technology can help advance their cancer research.

## Key facts

- **NIH application ID:** 10769334
- **Project number:** 2P30CA016087-43
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Youssef Zaim Wadghiri
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $38,853
- **Award type:** 2
- **Project period:** 1996-12-01 → 2029-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10769334

## Citation

> US National Institutes of Health, RePORTER application 10769334, Preclinical Imagining Labs (2P30CA016087-43). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10769334. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*